Livtencity - (200 mg ; Tablet)

Generic Name	Maribavir	Innovator	Takeda
Dosage	200 mg ; Tablet	Branded US Sales	Less Than $1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	Less Than 5
Other ANDA developers	Less Than 5	Tentative Approvals	None
Final Approvals	None	Generic Launches	None
Indication	LIVTENCITY is a cytomegalovirus (CMV) pUL97 kinase inhibitor indicated for the treatment of adults and pediatric patients (12 years of age and older and weighing at least 35 kg) with post-transplant CMV infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir or foscarnet.
Complexities	Yes

Executive Summary

Patent Status

Launch Timelines and Competition

Company	FTF Status / 180 days exclusivity	30-Months stay	Current Litigation Status	Current Approval Status	Likelihood of launch
**** ******	*** \ *********	*** **, ****	*******	****	*** ****** *** ****
****** ******	*** \ *********	*** **, ****	*******	****	*** ****** *** ****
*** ******	*** \ *********	*** **, ****	*******	****	*** ****** *** ****

Chronology Of Events